Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%.
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Amicus Therapeutics, Inc. (FOLD) is looking like an interesting pick, as it just reached a key level of support. FOLD's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
The consensus price target hints at a 43.4% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
'Boring' Amicus Therapeutics Is Making Progress
Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is missing this year and could partially explain the lack of the year-to-date share price momentum. Pombiliti+Opfolda's launch is progressing well, with patients switching from both Nexviazyme and Lumizyme.
